What Is Small Lymphocytic Lymphoma (SLL)?

Small lymphocytic lymphoma (SLL) is a slow-growing cancer of B cells that shows up mainly in the lymph nodes and sometimes the spleen, without the high numbers of circulating cancer cells in the blood that define its close relative, chronic lymphocytic leukemia (CLL). The World Health Organization classifies CLL and SLL as different manifestations of the same disease, and for most purposes they are managed identically. But the distinction matters to patients who hear the word “lymphoma” and want to know what it means for them in practical terms, from diagnosis through treatment and long-term monitoring.

SLL and CLL Are the Same Disease in Different Locations

The simplest way to understand SLL is as the tissue version of CLL. In CLL, the malignant B cells accumulate in the bloodstream, producing a measurable lymphocytosis on a routine blood count. In SLL, the same type of cell builds up in the lymph nodes, spleen, or other organs while the blood count stays relatively normal. Both diseases share the same immunophenotype, meaning the cancer cells carry the same surface markers, and both are treated with the same drugs.

Despite being lumped together, there are subtle molecular differences. SLL cells tend to show different patterns of chemokine receptor expression, with reduced levels of certain receptors that influence where the cells settle and how they migrate. Genetic differences have also been noted: SLL shows a higher rate of trisomy 12 and a lower rate of a common chromosome 13 deletion compared to CLL.¹ These molecular quirks may explain why SLL tends to stay in the tissues rather than flooding the bloodstream, though researchers are still working out the full picture.

Who Gets SLL and How Common Is It

SLL is considerably less common than CLL. During a large surveillance period from 1993 to 2004 in the United States, the incidence rate for SLL was about 1.3 per 100,000 person-years, compared to roughly 3.8 for CLL.² Men are diagnosed more often than women, with SLL showing a male-to-female ratio of about 1.7 to 1. Incidence rises steeply with age across all groups, though CLL rates climb more sharply in older adults than SLL rates do.

There are also racial disparities. White populations have the highest incidence, while rates among Black Americans are about 25% lower and rates among Asian and Pacific Islander populations are roughly 77% lower.³ The reasons for this variation are not fully understood but likely involve a mix of genetic susceptibility and environmental factors that researchers have not yet pinned down.

What SLL Looks and Feels Like

Many people with SLL have no symptoms at all when they are diagnosed. The disease is often found by accident, when a doctor notices swollen lymph nodes during a physical exam or when imaging done for another reason picks up enlarged nodes. Some patients do notice painless lumps in the neck, armpits, or groin. Others present with an enlarged spleen, fatigue, or signs of low blood counts such as easy bruising or frequent infections. A smaller number experience what are called B symptoms: fevers, drenching night sweats, or unexplained weight loss.⁴

Because SLL is so often indolent and asymptomatic, the diagnosis can feel anticlimactic. A biopsy of an enlarged lymph node reveals the characteristic small, round B cells, and the pathologist looks for features that nail down the diagnosis. The hallmark immunohistochemical finding is that the cells are positive for both CD5 and CD23, a combination that separates SLL from other slow-growing lymphomas such as follicular lymphoma or marginal zone lymphoma.⁵ A newer marker, a protein called lymphoid enhancer-binding factor 1, is highly specific for CLL/SLL and helps when the usual stains are ambiguous.

The Borderline Between SLL and Something Even More Indolent

Not every biopsy that shows CLL-type cells means someone has overt SLL. Researchers have proposed a borderline category for cases where a tissue sample contains the right type of cells but the lymph nodes are not truly enlarged and the tissue lacks the characteristic structures called proliferation centers. These cases behave more like monoclonal B-cell lymphocytosis, a precursor condition, than like true lymphoma. One group of investigators has suggested calling these findings “tissue involvement by CLL/SLL-like cells of uncertain significance,” essentially cautioning against labeling someone with a cancer diagnosis when their disease may never progress.⁶

This distinction matters because a lymphoma diagnosis carries psychological weight and insurance implications. Overtreating someone whose disease would never cause them trouble is a real concern in indolent lymphomas, and pathologists are increasingly careful about separating genuine SLL from incidental tissue findings.

Proliferation Centers and What Drives the Disease

Under the microscope, SLL tissue often contains pale-staining clusters called proliferation centers. These are areas where the cancer cells are actively dividing and receiving survival signals, and they are considered a distinctive feature of CLL/SLL that you do not see in most other indolent lymphomas. Research suggests that proliferation centers serve as hubs for B-cell receptor signaling, a key survival pathway for these malignant cells. The morphology of these centers may even correlate with how aggressive the disease behaves.⁷

B-cell receptor signaling is central to understanding why CLL/SLL cells survive and grow. The malignant B cells appear to receive chronic stimulation through their receptors, and the pattern of their immunoglobulin genes reveals two major subsets. One subset uses unmutated immunoglobulin genes (called IGHV-unmutated), and these patients tend to have a more aggressive clinical course. The other subset has mutated genes (IGHV-mutated), and these patients generally do better.⁸ This distinction is one of the most important prognostic markers in CLL/SLL and increasingly influences treatment decisions.

Prognostic Markers That Shape the Outlook

Beyond IGHV mutation status, several other factors help predict how SLL will behave over time. TP53 mutations, which disable one of the cell’s most important tumor-suppressor genes, are associated with a poor prognosis.⁹ Patients with TP53 abnormalities tend to respond poorly to traditional chemotherapy and are usually steered toward newer targeted treatments from the outset.

Flow cytometry, the technique used to count and characterize the cancer cells, can also offer clues. Higher levels of CD38 expression on the cell surface track with IGHV-unmutated disease and a worse prognosis.¹⁰ These markers do not change the diagnosis, but they help doctors and patients gauge how watchful they need to be and how quickly treatment might be needed.

Watch and Wait Is Still Standard, but Not Easy

For most people diagnosed with SLL who have no symptoms and no rapidly growing disease, the standard approach is active surveillance. Doctors monitor blood counts, examine lymph nodes, and check in regularly, but they do not start treatment until there is a clear reason to do so. The rationale is straightforward: since available treatments do not cure SLL, starting them early when the disease is not causing problems exposes the patient to side effects without a proven survival benefit.

That said, watch and wait is psychologically difficult. Patients often struggle with the idea that they have cancer but are not receiving treatment, and some describe significant anxiety during surveillance periods. There is also a biological concern: leaving the disease untreated may allow harmful mutations to accumulate over time, potentially making the cancer harder to treat later. This worry has prompted some researchers to explore early intervention strategies, though for now, the evidence does not clearly support treating asymptomatic patients.¹¹

Targeted Therapies Have Replaced Chemotherapy

When SLL does need treatment, the landscape has shifted dramatically over the past decade. Chemotherapy combinations were once the standard, but they have largely been replaced by targeted drugs that home in on specific survival pathways the cancer cells depend on. Two main classes dominate current practice.

BTK inhibitors block Bruton’s tyrosine kinase, a protein that sits in the B-cell receptor signaling pathway and helps keep the cancer cells alive. Ibrutinib was the first approved drug in this class and has the longest track record, though it comes with cardiovascular side effects and bleeding risks because it also hits other kinases beyond its intended target. Second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more selective, which translates to fewer off-target side effects while maintaining strong efficacy.¹²

The other major drug is venetoclax, which works by a completely different mechanism. Instead of blocking B-cell receptor signaling, it targets a protein called BCL-2 that prevents the cancer cells from undergoing programmed cell death. By disabling this survival protein, venetoclax essentially flips the “self-destruct” switch in the malignant cells.¹³ Venetoclax is given as a fixed-duration regimen rather than continuously, which appeals to patients who prefer a defined treatment endpoint.

When Targeted Drugs Stop Working

As effective as BTK inhibitors and venetoclax are, resistance develops in a meaningful fraction of patients. The most common mechanism is straightforward: the cancer cells acquire mutations in the very gene the drug targets. For BTK inhibitors, mutations in the BTK gene alter the protein’s shape so the drug can no longer bind effectively. Depending on the specific drug and clinical setting, acquired BTK mutations show up in anywhere from 10% to 80% of patients who progress on treatment.¹⁴

A similar story plays out with venetoclax. Mutations in the BCL-2 gene allow the protein to keep doing its survival job while shrugging off the drug. Several specific BCL-2 mutations have been identified across independent patient groups, all of which reduce venetoclax binding while preserving the protein’s cancer-promoting function.¹⁵ This makes sequencing treatments, the order in which drugs are given over time, a critical strategic decision for doctors managing SLL.

Ultra-deep sequencing studies have revealed just how complicated resistance can get. Individual patients may develop multiple resistance mutations simultaneously, sometimes in different genes. One patient studied after progressing on zanubrutinib was found to carry several known resistance mutations in both BTK and another gene called PLCG2. When that patient was switched to pirtobrutinib, a newer BTK inhibitor, some mutations were suppressed but others grew, illustrating the cat-and-mouse nature of targeted therapy.¹⁶

Pirtobrutinib and the Next Wave of Treatment

Pirtobrutinib represents a genuinely new approach. Unlike ibrutinib, acalabrutinib, and zanubrutinib, which all bind permanently to the BTK protein (called covalent binding), pirtobrutinib binds reversibly. This means it can still work against many of the mutations that defeat the older drugs. In a trial of patients with CLL or SLL who had already failed a covalent BTK inhibitor, pirtobrutinib produced an overall response rate of about 73%, rising to roughly 82% when partial responses with residual lymphocytosis were included. The median time before the disease progressed again was about 19 and a half months.¹⁷ For a heavily pretreated population, those numbers are encouraging and have earned pirtobrutinib a place in the treatment sequence for patients who run out of standard options.

Richter Transformation

The most feared complication of SLL is Richter transformation, in which the slow-growing lymphoma converts into an aggressive large-cell lymphoma. This happens in a small but not negligible percentage of patients, and when it does, the prognosis changes dramatically. Survival after Richter transformation is generally measured in months to a couple of years, and many patients progress quickly even after aggressive chemotherapy.¹⁸ Advanced-stage disease and prior treatment for CLL/SLL are both associated with worse outcomes once transformation occurs.¹⁹

Suspecting Richter transformation usually starts with clinical clues: rapidly growing lymph nodes, new B symptoms, rising blood markers. PET/CT scanning plays an important role because transformed tissue tends to light up much more brightly than indolent SLL. A systematic review and meta-analysis found that using a threshold of high metabolic activity on PET (an SUV max of 5 or above) provides the best sensitivity for selecting biopsy sites when transformation is suspected. If a biopsy is not feasible, a higher threshold of 10 or above provides better specificity to guide treatment decisions.²⁰ A tissue biopsy remains the gold standard for confirming transformation, but imaging helps direct where that biopsy should be taken.

Immune Dysfunction, Infections, and Autoimmune Problems

SLL does more than just grow. It disrupts the immune system in ways that create problems well beyond the lymphoma itself. Infections are a leading cause of illness and death in CLL/SLL patients. One analysis estimated severe infections at a rate of about 20 per 100 patient-years, and infections cause or contribute to over 35% of CLL-related deaths.²¹ The immune defect is multifaceted: patients often have low immunoglobulin levels, impaired T-cell function, and problems with other immune cells. Targeted therapies have improved survival but have not resolved this underlying vulnerability.

Autoimmune complications affect roughly 10% of patients. The most common is autoimmune hemolytic anemia, where the body destroys its own red blood cells, followed by immune thrombocytopenia, where platelets are targeted. A smaller number develop pure red cell aplasia. In one long-term cohort, about 9% of patients developed autoimmune cytopenias, and most responded to immunosuppressive treatment, though serious infections during that treatment were common.²² An important finding from that study was that developing autoimmune complications did not predict a worse cancer outcome, which can be reassuring for patients who face these secondary problems.

Vaccines Work Poorly, but Still Matter

The immune dysfunction in SLL has a very practical consequence: vaccines do not work as well as they do in healthy people. A study of the recombinant herpes zoster (shingles) vaccine in CLL patients found that only about 45% mounted an antibody response at three months, significantly lower than the roughly 63% seen in historical controls. The cellular immune response was even more disappointing: only about 29% of participants achieved both an antibody and a cellular response to the vaccine.²³ Patients on BTK inhibitors fared particularly poorly on the cellular side, with only about a third mounting a T-cell response compared to nearly three-quarters of untreated patients.

The clinical takeaway is not to skip vaccines but to get them earlier, ideally before starting treatment, and to recognize that they offer only partial protection. Patients and their doctors need to think about vaccination timing strategically, especially for preventable infections like shingles, pneumonia, and influenza. Low immunoglobulin levels and ongoing BTK inhibitor therapy were both linked to weaker vaccine responses, so patients with these risk factors may need additional protective strategies such as immunoglobulin replacement therapy for those with recurrent infections.

Living with SLL and Treatment-Related Quality of Life

Because SLL often spans years or even decades, quality of life during treatment is not a secondary concern. It is arguably as important as the drug’s ability to shrink lymph nodes. The HELIOS trial, which studied ibrutinib added to a chemotherapy-antibody backbone in relapsed CLL/SLL, found that for most patients, adding the targeted drug did not make quality of life worse. Patients who entered the trial with the worst fatigue and physical functioning actually showed greater improvement with ibrutinib than without it.²⁴ For patients who feel well at baseline, the benefit of adding treatment is harder to measure in quality-of-life terms, which circles back to why doctors are cautious about starting treatment when it is not yet needed.

Fatigue is the most commonly reported symptom across the disease course, and it does not always correlate with how much cancer is present. Some patients with minimal disease burden feel exhausted, while others with bulky nodes have surprising energy. Managing fatigue in SLL often requires a combination of treating the disease when it is contributing, addressing other causes like anemia or thyroid dysfunction, and supporting exercise and activity even when the instinct is to rest. The long timeframe of SLL means that the relationship between a patient and their hematologist is more of a years-long partnership than a short treatment episode, with ongoing adjustments to monitoring, treatment, and supportive care as the disease evolves.